The clinical utility of Tg-IMAs monitoring for tumor persistence or recurrence in DTC patients is severely compromised by the interference of Tg-Abs and HAs, resulting in either an over- or underestimation of serum Tg concentration. The gene discussed is TG; the disease is neoplasm.